Company intelligence / Profile preview

AvenCell Therapeutics

Cambridge/WATERTOWN, Massachusetts, United Statesavencell.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

AvenCell has demonstrated controllability of its Universal CAR-T Cells with manageable toxicity in early clinical studies. Its lead program AVC‑101 targets CD123 for relapsed/refractory AML. The company’s allogeneic program AVC‑201 has received EMA approval for a clinical trial application. Early data show safety and efficacy signals for their universal CAR-T approach.

Therapeutic areas: OncologyImmunology
Modalities: Universal switchable CAR-T cell therapies (autologous and allogeneic)adoptive T cell therapy
Industry: Biotech

Drug pipeline

14 assets

AVC-203

13 more assets in the full pipeline.

Request access →

Partnerships

Blackstone Life Sciences (founder/investor)Cellex Cell ProfessionalsIntellia Therapeutics (CRISPR/Cas9 license)

Beyond the preview

Go deeper on AvenCell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AvenCell Therapeutics.

Explore the full profile